Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

Open access
Logtenberg, Meike E. W., Jansen, J. H. Marco, Raaben, Matthijs, Toebes, Mireille, Franke, Katka, Brandsma, Arianne M., Matlung, Hanke L., Fauster, Astrid, Gomez-Eerland, Raquel, Bakker, Noor A. M., van der Schot, Simone, Marijt, Koen A., Verdoes, Martijn, Haanen, John B. A. G., van den Berg, Joost H., Neefjes, Jacques, van den Berg, Timo K., Brummelkamp, Thijn R., Leusen, Jeanette H. W., Scheeren, Ferenc A., Schumacher, Ton N. · 2019 · Nature Medicine

Abstract

Cancer cells can evade immune surveillance through the expression of inhibitory ligands that bind their cognate receptors on immune effector cells. Expression of programmed death ligand 1 in tumor microenvironments is a major immune checkpoint for tumor-specific T cell responses as it binds to programmed cell death protein-1 on activated and dysfunctional T cells1. The activity of myeloid cells such as macrophages and neutrophils is likewise regulated by a balance between stimulatory and inhibitory signals. In particular, cell surface expression of the CD47 protein creates a ‘don’t eat me’ signal on tumor cells by binding to SIRPα expressed on myeloid cells2–5. Using a haploid genetic screen, we here identify glutaminyl-peptide cyclotransferase-like protein (QPCTL) as a major component of the CD47-SIRPα checkpoint. Biochemical analysis demonstrates that QPCTL is critical for pyroglutamate formation on CD47 at the SIRPα binding site shortly after biosynthesis. Genetic and pharmacological interference with QPCTL activity enhances antibody-dependent cellular phagocytosis and cellular cytotoxicity of tumor cells. Furthermore, interference with QPCTL expression leads to a major increase in neutrophil-mediated killing of tumor cells in vivo. These data identify QPCTL as a novel target to interfere with the CD47 pathway and thereby augment antibody therapy of cancer. QPCTL is a modifier of CD47-SIRPα binding and its blockade enhances macrophage- and neutrophil-mediated antibody dependent cellular cytotoxicity towards tumor cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0356-z

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 240

Metadata

Authors
Logtenberg, M. E. W., Jansen, J. H. M., Raaben, M., Toebes, M., Franke, K., Brandsma, A. M., Matlung, H. L., Fauster, A., Gomez-Eerland, R., Bakker, N. A. M., van der Schot, S., Marijt, K. A., Verdoes, M., Haanen, J. B. A. G., van den Berg, J. H., Neefjes, J., van den Berg, T. K., Brummelkamp, T. R., Leusen, J. H. W., Scheeren, F. A., & Schumacher, T. N.
Venue
Nature Medicine
Published
2019-03-04
Volume
25
Issue
4
Pages
612-619
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2918786033
Cited by
240
References
11
FWCI
8.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41591-019-0356-z
The paper
Logtenberg, M. E. W., Jansen, J. H. M., Raaben, M., Toebes, M., Franke, K., Brandsma, A. M., Matlung, H. L., Fauster, A., Gomez-Eerland, R., Bakker, N. A. M., van der Schot, S., Marijt, K. A., Verdoes, M., Haanen, J. B. A. G., van den Berg, J. H., Neefjes, J., van den Berg, T. K., Brummelkamp, T. R., Leusen, J. H. W., . . . Schumacher, T. N. (2019). Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nature Medicine. https://doi.org/10.1038/s41591-019-0356-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.